Autolus Therapeutics vs Iovance Biotherapeutics
AUTL and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and IOVA compare
Iovance Biotherapeutics is the larger company, worth 11 times as much as Autolus Therapeutics ($3.4B against $303M).
Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 34.5% for Iovance Biotherapeutics).
Iovance Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −89.1% compared with −239% at Autolus Therapeutics.
Iovance Biotherapeutics scores higher on the StockData Score (9 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | IOVA |
|---|---|---|
| Size and price | ||
| Market cap | $303M | $3.4B |
| Share price | $1.14 | $7.55 |
| Change, 1 year | −10.9% | 213% |
| Change, 5 years | −81.8% | −59.2% |
| Beta (5Y) | 3.40 | 1.45 |
| Employees | 754 | 975 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.6× (better) | 10.5× |
| P/B | 4.1× (better) | 4.6× |
| FCF yield | −76.7% | −8.7% (better) |
| Fair value | $1.41 | $4.06 |
| Margin of safety | 19.3% (better) | −86.1% |
| Growth | ||
| Revenue growth (TTM) | 292% (better) | 34.5% |
| Profitability | ||
| Gross margin | 15.7% | 48.4% (better) |
| Operating margin | −211% | −92.7% (better) |
| Net margin | −239% | −89.1% (better) |
| FCF margin | −198% | −91.2% (better) |
| Return on equity | −133% | −40.4% (better) |
| Return on invested capital | – | −57.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.9× | – |
| Current ratio | 4.89 (better) | 4.35 |
| Altman Z-score | −4.58 | 6.73 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −8.5% |
| Shareholder yield | 0.00% (better) | −8.5% |
| Ownership | ||
| Held by institutions | 49.7% | 63.3% |
| Held by insiders | 24.6% | 0.39% |
| Insider net buying, 12 months | −$15.7K | – |
| Short interest, % of float | – | 14.4% |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.